EducationRecent
In 1992, Dr John Eng discovered a molecule in Gila monster venom; decades later, his finding helped pave the way for widely used type 2 diabetes medicines
Times of India — Education✓
Original Reporting
AI EXECUTIVE SUMMARY
In 1992 Dr. John Eng identified the peptide exendin‑4 in Gila monster venom. This finding led to the development of exenatide, marketed as Byetta, the first FDA‑approved GLP‑1 receptor agonist for type 2 diabetes. Eng’s research established the therapeutic potential of targeting the GLP‑1 receptor, paving the way for later drugs such as Ozempic.
WHY IT MATTERS
It demonstrates how early biomedical research can evolve into widely used diabetes therapies that benefit millions of patients.
Dr John Eng, a physician and researcher at the James J. Peters VA Medical Center in the Bronx, played a pivotal role in the scientific history behind modern GLP-1 medicines. In 1992, his research identified exendin-4 in Gila monster venom, leading to exenatide, marketed as Byetta, the first FDA-approved GLP-1 receptor agonist for type 2 diabetes. Although Eng did not discover Ozempic or semaglutide, his work helped establish the therapeutic potential of targeting the GLP-1 receptor.
This story was originally reported by Times of India — Education. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.
ALSO REPORTED BY OTHER SOURCES (2)
More and more undergrads are living at home. That’s a crying shame – here’s why | Rohan Sathyamoorthy
Emergency measures needed to stop teachers quitting, say Lib Dems
Community Sentiment & Coverage Reliability
Crowd-sourced evaluation based on verified reader feedback
Rate Coverage Tone:
No reader evaluations recorded yet — be the first to rate the coverage tone above!
Quick Story Reactions:
Community Discussion (0)
Join the Community Discussion
Sign in or create a free reader account to post comments, upvote analysis, and share your perspective.